(Q37855303)

24 August 2017

1 reference

title

Treatment recommendations for metastatic colorectal cancer (English)

1 reference

24 August 2017

1 reference

Josep Tabernero Caturla

9

1 reference

24 August 2017

Enrique Aranda

1

1 reference

24 August 2017

Albert Abad

2

1 reference

24 August 2017

Alfredo Carrato

3

1 reference

24 August 2017

Andrés Cervantes

4

1 reference

24 August 2017

Jesús García-Foncillas

5

1 reference

24 August 2017

Pilar García Alfonso

6

1 reference

24 August 2017

Rocío García Carbonero

7

1 reference

24 August 2017

Auxiliadora Gómez España

8

1 reference

24 August 2017

Eduardo Díaz-Rubio

10

1 reference

24 August 2017

publication date

1 March 2011

1 reference

24 August 2017

number of pages

17

1 reference

Clinical and Translational Oncology

inferred from page(s)

published in

1 reference

24 August 2017

volume

13

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

162-178

1 reference

Cancer mortality in the European Union, 1970-2003, with a joinpoint analysis

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

21 January 2018

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Estimates of the cancer incidence and mortality in Europe in 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Towards a pan-European consensus on the treatment of patients with colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Colorectal liver metastases: CT, MR imaging, and PET for diagnosis--meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Regulation of human dihydropyrimidine dehydrogenase: implications in the pharmacogenetics of 5-FU-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Should DPD analysis be required prior to prescribing fluoropyrimidines?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

High thymidylate synthase expression in colorectal cancer with microsatellite instability: implications for chemotherapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Actual 10-year survival after resection of colorectal liver metastases defines cure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Survival after hepatic resection in metastatic colorectal cancer: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Complete response of colorectal liver metastases after chemotherapy: does it mean cure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

The continuum of care: a paradigm for the management of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Preliminary results of intraperitoneal chemohyperthermia with oxaliplatin in peritoneal carcinomatosis of colorectal origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Follow-up of patients treated by cytoreduction and chemotherapy for peritoneal carcinomatosis of colorectal origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Expandable metal stents for the treatment of colonic obstruction: techniques and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Covered metal stents for management of inoperable malignant colorectal strictures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Outcome after simultaneous colorectal and hepatic resection for colorectal cancer with synchronous metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: A Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-011-0636-7

The management of synchronous peritoneal carcinomatosis and hematogenous metastasis from colorectal cancer

21 January 2018

1 reference

12 December 2020

Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer

1 reference

12 December 2020

Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome

1 reference

12 December 2020

Use of surgery among elderly patients with stage IV colorectal cancer

1 reference

12 December 2020

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

1 reference

12 December 2020

Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab

1 reference

12 December 2020

Simultaneous colorectal and hepatic resections for colorectal cancer: postoperative and longterm outcomes

1 reference

12 December 2020

UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan

1 reference

12 December 2020

Long-term prognostic value of positive peritoneal washing in colon cancer

1 reference

12 December 2020

Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology

1 reference

12 December 2020

Combined colon and hepatic resection for synchronous colorectal liver metastases

1 reference

12 December 2020

Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1

1 reference

12 December 2020

Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates

1 reference

12 December 2020

Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?

1 reference

12 December 2020

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study

1 reference

12 December 2020

Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors

1 reference

12 December 2020

Malignant colorectal obstruction treated by means of self-expanding metallic stents: effectiveness before surgery and in palliation

1 reference

12 December 2020

Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group

1 reference

12 December 2020

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

12 December 2020

Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer

1 reference

12 December 2020

Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil pl

1 reference

12 December 2020

Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms

1 reference

12 December 2020

Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study

1 reference

12 December 2020

Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer

1 reference

12 December 2020

Hepatic resection for colorectal liver metastases. Influence on survival of preoperative factors and surgery for recurrences in 80 patients

1 reference

12 December 2020

Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Intraoperative Chemotherapy for Peritoneal Carcinomatosis Arising From Colon Adenocarcinoma

1 reference

12 December 2020

Major liver resections synchronous with colorectal surgery

1 reference

12 December 2020

Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors

1 reference

12 December 2020

Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial

1 reference

12 December 2020

Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study

1 reference

12 December 2020

VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon

1 reference

12 December 2020

A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer.

1 reference

12 December 2020

Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie

1 reference

12 December 2020

Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases

1 reference

12 December 2020

Management of liver metastases from colorectal cancer.

1 reference

12 December 2020

Simultaneous resection of colorectal primary tumour and synchronous liver metastases

1 reference

12 December 2020

Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin

1 reference

12 December 2020

The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer

1 reference

12 December 2020

Interval hepatic resection of colorectal metastases improves patient selection*

1 reference

12 December 2020

A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer

1 reference

12 December 2020

Is simultaneous hepatectomy and intestinal anastomosis safe?

1 reference

12 December 2020

Swedish experience with peritonectomy and HIPEC. HIPEC in peritoneal carcinomatosis

1 reference

12 December 2020

A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer

1 reference

12 December 2020

The role of thymidylate synthase as a molecular biomarker

1 reference

12 December 2020

Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery

1 reference

12 December 2020

Radiology of peritoneal carcinomatosis.

1 reference

12 December 2020

Peritoneal carcinomatosis from colorectal cancer

1 reference

12 December 2020

Peritoneal carcinomatosis from adenocarcinoma of the colon

1 reference

12 December 2020

UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters

1 reference

12 December 2020

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

12 December 2020

Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy

1 reference

12 December 2020

Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival

1 reference

12 December 2020

Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal

1 reference

12 December 2020

Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis.

1 reference

12 December 2020

BRAFMutation in Metastatic Colorectal Cancer

1 reference

12 December 2020

CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR

1 reference

12 December 2020

10.1007/S12094-011-0636-7

Identifiers

DOI

1 reference

24 August 2017

1 reference